TrialHuman vaccines & immunotherapeutics2023

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.

Sanjay S Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.